Topoisomerase I targeting agents in small-cell lung cancer.
The topoisomerase I inhibitors such as irinotecan and topotecan are active agents against small-cell lung cancer that are effective in treating not only chemotherapy-naïve tumors but also progressed-stage tumors after treatment with cisplatin-based regimens, because their mechanism of antitumor activity differs from that of the agents included in standard chemotherapy for small-cell lung cancer. Etoposide plus cisplatin or etoposide plus cisplatin alternating with cyclophosphamide, doxorubicin, and vincristine is considered the standard regimen for small-cell lung cancer. No new standard combination chemotherapy for small-cell lung cancer has been developed over the past decade. Irinotecan with cisplatin is now established as a new standard chemotherapy for extensive-stage small-cell lung cancer based on the results of the Japan Clinical Oncology Group trial. Of course, confirmation through phase III studies will be extremely important. The Japan Clinical Oncology Group is intensively investigating other irinotecan-containing regimens and the incorporation of irinotecan into treatment of patients with limited-stage small-cell lung cancer.